Published in Hepatitis Weekly, September 20th, 2004
The additional safety and efficacy data from this 8 patient cohort will enable a re-evaluation of the decision to resume the highest dosing arm of the trial.
Enrollment of new patients was halted by the company in May after 1 patient in the highest dosing arm of the trial did not survive the transplant operation.
The medical examiner...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.